Oncostatin M stimulates excessive extracellular matrix accumulation in a transgenic mouse model of connective tissue disease

Journal of Molecular Medicine

Volumn 76, Issue 1, 1998, Pages 61-69

  Bamber, Bruce ^a,b,d   Reife, Robert A ^d   Haugen, Harald S ^d   Clegg, Christopher H ^a,c,d,e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c ZymoGenetics Corp

^d BRISTOL MYERS SQUIBB   (United States)

^e ZYMOGENETICS INC   (United States)

Author keywords

Fibrosis; Neuropeptide; Oncostatin; Pancreas; SPARC; Transgenic

Indexed keywords

CYTOKINE; ONCOSTATIN M;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONNECTIVE TISSUE DISEASE; DISEASE COURSE; EXTRACELLULAR MATRIX; FIBROSIS; GENE EXPRESSION; IN SITU HYBRIDIZATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; TRANSGENIC MOUSE; WOUND HEALING;

EID: 0031932442     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s109-1998-8105-3     Document Type: Article

References (29)

1. Seibold JR (1993) Connective tissue diseases characterized by fibrosis. In: Kelley WN, Harris ED, Ruddy S, Sledge CB (eds) Textbook of rheumatology. Saunders, Philadelphia, pp 1113-1143
2. Raghow R (1994) The role of extracellular matrix in postinflammatory wound healing and fibrosis. FASEB J 8:823-831
3. Kovacs EJ, DiPietro LA (1994) Fibrogenic cytokines and connective tissue production. FASEB J 8:854-860
4. Wahl SM (1994) Transforming growth factor beta: the good, the bad, and the ugly. J Exp Med 180:1587-1590
5. Lee M-S, Gu D, Feng L, Curriden S, Arnush M, Krahl T, Gurushanthaiah D, Wilson W, Loskutoff DL, Fox H, Sarvetnick N (1995) Accumulation of extracellular matrix and developmental dysregulation in the pancreas by transgenic production of transforming growth factor-β1. Am J Pathol 147:42-52
6. Frazier K, Kothapalli D, Klapper H, Grotendorst GR (1996) Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 107:404-411
7. Bruce AG, Linsley PS, Rose TM (1992). Oncostatin M. Prog Growth Factor Res 4:157-170
8. Gearing DP, Bruce AG (1992) Oncostatin M binds the high-affinity leukemia inhibitory factor receptor. New Biol 4:61-65
9. Mosley B, De Imus C, Friend D, Boiani N, Thoma B, Park LS, Cosman D (1996) Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem 271: 32635-3243
10. Wallace PM, MacMaster JF, Rillema JR, Rouleau KA, Hanson MB, Burstein SA, Shoyab M (1995) In vivo properties of oncostatin M. Ann N Y Acad Sci 762:42-54
11. Malik N, Haugen H S, Modrell B, Shoyab M, Clegg CH (1995) Developmental abnormalities in mice transgenic for bovine oncostatin M. Mol Cell Biol 15:2349-2358
12. Clegg CH, Rulffes JT, Wallace PM, Haugen HS (1996) Regulation of an extrathymic T-cell development pathway by oncostatin M. Nature 384:261-263
13. Richards CD, Shoyab M, Brown TJ, Gauldie J (1993) Selective regulation of metalloproteinase inhibitor (TIMP-1) by oncostatin M in fibroblasts in culture. J Immunol 150: 5596-5603
14. Richards CD, Langdon C, Botelho F, Brown TJ, Agro A (1996) Oncostatin M inhibits IL-1 induced expression of IL-8 and granulocyte-macrophage colony-stimulating factor by synovial and lung fibroblasts. J Immunol 156:343-349
15. Duncan MR, Hasan A, Berman B (1995) Oncostatin M stimulates collagen and glycosaminoglycan production by cultured normal dermal fibroblasts: insensitivity of sclerodermal and keloidal fibroblasts. J Invest Dermatol 104:128-133
16. Miles SA, Martinez-Maza O, Rezai A, Magpantay L, Kishimoto T, Nakamura S, Radka SF, Linsley PS (1992) Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells. Science 255:432-434
17. Rao MS, Symes A, Malik N, Shoyab M, Fink JS, Landis SC (1992) Oncostatin M regulates VIP expression in a human neuroblastoma cell line. Mol Neurobiol 3:865-868
18. Sun Y, Rao MS, Zigmond RE, Landis SC (1994) Regulation of vasoactive intestinal peptide expression in sympathetic neurons in culture and after axotomy: the role of cholinergic differentiation factor/leukemia inhibitory factor. J Neurobiol 25:415-430
19. Bamber BA, Masters BA, Hoyle GW, Brinster RL, Palmiter RD (1994) Leukemia inhibitory factor induces neurotransmitter switching in transgenic mice. Proc Natl Acad Sci USA 17:7839-7843
20. Campbell IL, Hobbs MV, Dockter J, Oldstone MB, Allison J (1994) Islet inflammation and hyperplasia induced by the pancreatic islet-specific overexpression of interleukin-6 in transgenic mice. Am J Pathol 145:157-166
21. Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan GA, Costantini F (1994) Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 13:1189-96
22. Russ J C (1986) Practical stereology. Plenum Press, New York
23. Reife RA, Shapiro RA, Bamber BA, Berry KK, Mick GE, Darveau RP (1995) Porphyromonas gingivalis lipopolysaccharide is poorly recognized by molecular components of innate host defense in a mouse model of early inflammation. Infect Immun 63:4686-4694
24. Lang RA, Cuthbertson RA, Dunn AR (1992) TNF alpha, IL-1 alpha and bFGF are implicated in the complex disease of GMCSF transgenic mice. Growth Factors 6:131-138
25. Sarvetnick N, Shizuru J, Liggitt D, Martin L, McIntyre B, Gregory A, Parslow T, Stewart T (1990) Loss of pancreatic islet tolerance induced by beta-cell expression of interferon-gamma. Nature 346:844-847
26. Frizell E, Liu SL, Abraham A, Ozaki I, Eghbali M, Sage EH, Zern MA (1995) Expression of SPARC in normal and fibrotic livers. Hepatology 21:847-854
27. Porter PL, Sage EH, Lane TF, Funk SE, Gown AM (1995) Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem 43:791-800
28. Westendorf JJ, Jelinek DF (1996) Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression. J Immunol 157:3081-3088
29. Benigni F, Fantuzzi G, Sacco S, Sironi M, Pozzi P, Dinarello CA, Sipe JD, Poli V, Cappelletti M, Paonessa G, Pennica D, Panayotatos N, Ghezzi P (1996) Six different cytokines that share gp130 as a receptor subunit, induce serum amyloid and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1. Blood 87:1851-1854